MX2020000785A - Metodos para la deteccion de discrasia de celulas plasmaticas. - Google Patents
Metodos para la deteccion de discrasia de celulas plasmaticas.Info
- Publication number
- MX2020000785A MX2020000785A MX2020000785A MX2020000785A MX2020000785A MX 2020000785 A MX2020000785 A MX 2020000785A MX 2020000785 A MX2020000785 A MX 2020000785A MX 2020000785 A MX2020000785 A MX 2020000785A MX 2020000785 A MX2020000785 A MX 2020000785A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- plasma cell
- detection
- cell dyscrasias
- determining
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6818—Sequencing of polypeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Computational Biology (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762535419P | 2017-07-21 | 2017-07-21 | |
| PCT/US2018/042712 WO2019018540A1 (en) | 2017-07-21 | 2018-07-18 | METHODS FOR DETECTION OF PLASMOCYTE DYSGLOBULINEMIA |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020000785A true MX2020000785A (es) | 2020-11-06 |
Family
ID=63244986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020000785A MX2020000785A (es) | 2017-07-21 | 2018-07-18 | Metodos para la deteccion de discrasia de celulas plasmaticas. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20190025311A1 (enExample) |
| EP (1) | EP3655553B1 (enExample) |
| JP (1) | JP7223741B2 (enExample) |
| KR (1) | KR102785072B1 (enExample) |
| CN (1) | CN111194356B (enExample) |
| AU (1) | AU2018304242B2 (enExample) |
| BR (1) | BR112020000791A2 (enExample) |
| DK (1) | DK3655553T3 (enExample) |
| ES (1) | ES2916450T3 (enExample) |
| IL (1) | IL271465B2 (enExample) |
| MX (1) | MX2020000785A (enExample) |
| PL (1) | PL3655553T3 (enExample) |
| WO (1) | WO2019018540A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020000791A2 (pt) | 2017-07-21 | 2020-07-21 | Liquid Biopsy Research LLC | métodos para detecção de discrasia de célula plasmática |
| EP4041886A1 (en) | 2019-10-10 | 2022-08-17 | Liquid Biopsy Research LLC | Compositions, methods and kits for biological sample and rna stabilization |
| CN111349705A (zh) * | 2020-03-18 | 2020-06-30 | 昆明医科大学 | circASXL1作为肺癌诊断标志物及其运用 |
| AU2021281287A1 (en) * | 2020-05-29 | 2023-01-19 | Bio-Techne Corporation | Use of microvesicle signature for the diagnosis and treatment of kidney transplant rejection |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005512557A (ja) | 2001-11-07 | 2005-05-12 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ アーカンソー | 遺伝子発現プロファイリングに基づく多発性骨髄腫の診断、予後、および治療標的候補の同定 |
| JP2004313167A (ja) | 2003-02-24 | 2004-11-11 | Joji Inasawa | 薬剤耐性マーカーおよびその利用 |
| EP1766086A4 (en) * | 2004-05-21 | 2009-10-28 | Univ Arkansas | USE OF GENETIC EXPRESSION PROFILING TO PREVENT THE CHANCE OF SURVIVAL OF A PATIENT WITH CANCER |
| EP2687608B1 (en) | 2005-06-08 | 2017-02-08 | Millennium Pharmaceuticals, Inc. | Methods for the identification, assessment, and treatment of patients with cancer therapy |
| CN102361991A (zh) * | 2009-01-02 | 2012-02-22 | 阿肯色大学托管委员会 | 硼替佐米在预测多发性骨髓瘤患者生存率中的应用 |
| WO2011152884A2 (en) * | 2010-06-04 | 2011-12-08 | Board Of Trustees Of The University Of Arkansas | 14 gene signature distinguishes between multiple myeloma subtypes |
| WO2013155048A1 (en) * | 2012-04-10 | 2013-10-17 | University Of Utah Research Foundation | Compositions and methods for diagnosing and classifying multiple myeloma |
| BR112020000791A2 (pt) | 2017-07-21 | 2020-07-21 | Liquid Biopsy Research LLC | métodos para detecção de discrasia de célula plasmática |
-
2018
- 2018-07-18 BR BR112020000791-9A patent/BR112020000791A2/pt active Search and Examination
- 2018-07-18 US US16/039,041 patent/US20190025311A1/en not_active Abandoned
- 2018-07-18 CN CN201880061441.9A patent/CN111194356B/zh active Active
- 2018-07-18 AU AU2018304242A patent/AU2018304242B2/en active Active
- 2018-07-18 JP JP2020502711A patent/JP7223741B2/ja active Active
- 2018-07-18 MX MX2020000785A patent/MX2020000785A/es unknown
- 2018-07-18 PL PL18755985.1T patent/PL3655553T3/pl unknown
- 2018-07-18 EP EP18755985.1A patent/EP3655553B1/en active Active
- 2018-07-18 ES ES18755985T patent/ES2916450T3/es active Active
- 2018-07-18 KR KR1020207004033A patent/KR102785072B1/ko active Active
- 2018-07-18 WO PCT/US2018/042712 patent/WO2019018540A1/en not_active Ceased
- 2018-07-18 DK DK18755985.1T patent/DK3655553T3/da active
-
2019
- 2019-12-16 IL IL271465A patent/IL271465B2/en unknown
-
2021
- 2021-10-14 US US17/501,168 patent/US12366575B2/en active Active
-
2025
- 2025-06-13 US US19/238,168 patent/US20260118360A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK3655553T3 (da) | 2022-06-20 |
| US20260118360A1 (en) | 2026-04-30 |
| CN111194356A (zh) | 2020-05-22 |
| IL271465A (en) | 2020-01-30 |
| AU2018304242B2 (en) | 2023-04-27 |
| BR112020000791A2 (pt) | 2020-07-21 |
| JP2020528274A (ja) | 2020-09-24 |
| AU2018304242A1 (en) | 2020-01-16 |
| ES2916450T3 (es) | 2022-07-01 |
| WO2019018540A1 (en) | 2019-01-24 |
| IL271465B2 (en) | 2023-08-01 |
| KR20200029528A (ko) | 2020-03-18 |
| US20230022417A1 (en) | 2023-01-26 |
| EP3655553B1 (en) | 2022-03-23 |
| PL3655553T3 (pl) | 2022-09-26 |
| US12366575B2 (en) | 2025-07-22 |
| KR102785072B1 (ko) | 2025-03-20 |
| IL271465B1 (en) | 2023-04-01 |
| CA3067730A1 (en) | 2019-01-24 |
| US20190025311A1 (en) | 2019-01-24 |
| CN111194356B (zh) | 2024-04-23 |
| JP7223741B2 (ja) | 2023-02-16 |
| EP3655553A1 (en) | 2020-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018000649A1 (es) | Nuevos compuestos bicíclicos como inhibidores duales de atx / ca | |
| BR112015022763A8 (pt) | sensor para detectar um analito | |
| CL2017002604A1 (es) | Sondas duales silenciadoras | |
| EA201591750A1 (ru) | Антитела против b7-h4 и иммуноконъюгаты | |
| BR112016006319A2 (pt) | inibidores de irak e usos dos mesmos | |
| BR112014019331A8 (pt) | anticorpos para cd47 e métodos de uso desses | |
| CO7151531A2 (es) | Anticuerpos e inmunoconjugados contra ly6e y métodos de uso | |
| ECSP13012394A (es) | Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa | |
| MX2023000563A (es) | Metodos y procesos para evaluacion no invasiva de variaciones geneticas. | |
| EA201791029A1 (ru) | Антитела против интерлейкина-33 и их применение | |
| PL3060582T3 (pl) | Testy do oznaczania biomarkerów układu kalikreiny osoczowej | |
| ECSP13012786A (es) | Anticuerpos anti-pcsk9 y métodos de uso | |
| MX2017005888A (es) | Dispositivos, sistemas y metodos para la deteccion de analitos. | |
| EA201791578A1 (ru) | Панель биомаркеров для обнаружения рака | |
| EP4462120A3 (en) | Methods for predicting response to parp inhibitors | |
| MX2016002423A (es) | Composiciones y metodos de diagnostico para el tratamiento de glioblastoma. | |
| IN2014DN04645A (enExample) | ||
| CR20150247A (es) | Anticuerpos de antihemaglutinina y métodos de uso | |
| EA201490778A1 (ru) | АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ | |
| IL258637A (en) | Immunoassay to detect cleaved high molecular weight kininogen | |
| MX2014014376A (es) | Anticuerpos de anti-biotina y metodos de uso. | |
| CL2014002211A1 (es) | Sistema para determinar una propiedad de un objeto que comprende una disposicion de induccion para generar un impulso de fluido, un detector para detectar la vibracion fisical del objeto, un procesador acoplado al detector para determinar la propiedad del objeto; metodo para determinar una propiedad de un objeto; y una valvula. | |
| BR112014024023A2 (pt) | anticorpos idiotípicos anti-hcmv e usos dos mesmos | |
| EA201690559A1 (ru) | Способы определения ответа на терапию | |
| BR112017021186A2 (pt) | ?método para detectar a presença de bactérias produtoras de beta-lactamase? |